[HTML][HTML] Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus

P Bhandari, AC Bateman, RL Mehta, BSF Stacey… - BMC cancer, 2006 - Springer
P Bhandari, AC Bateman, RL Mehta, BSF Stacey, P Johnson, IA Cree, F Di Nicolantonio
BMC cancer, 2006Springer
Background COX-2 expression in tumour cells has been associated with poor prognosis in
gastrointestinal and non-gastrointestinal cancers. The aim of our study was to test the
hypothesis that higher levels of COX-2 expression are prognostically related to poor clinico-
pathologic features in adenocarcinoma of the oesophagus. Methods We reviewed the
records of 100 consecutive patients undergoing resection for adenocarcinoma of the
oesophagus to collect data on T-stage, N-stage, tumour recurrence and survival. T & N …
Background
COX-2 expression in tumour cells has been associated with poor prognosis in gastrointestinal and non-gastrointestinal cancers. The aim of our study was to test the hypothesis that higher levels of COX-2 expression are prognostically related to poor clinico-pathologic features in adenocarcinoma of the oesophagus.
Methods
We reviewed the records of 100 consecutive patients undergoing resection for adenocarcinoma of the oesophagus to collect data on T-stage, N-stage, tumour recurrence and survival. T & N-stage was further confirmed by histological examination. COX-2 protein expression was assessed by immunohistochemistry in all patients and COX-2 m-RNA expression was measured by quantitative RT-PCR in a small group of patients.
Results
Higher levels of COX-2 expression were associated with higher T stage (p = 0.008), higher N stage (p = 0.049), increased risk of tumour recurrence (p = 0.01) and poor survival (p = <0.001). A COX-2 score of >200 was associated with a median survival of 10 months compared to 26 months with a score of <200 (p = <0.001).
Conclusion
Higher levels of COX-2 expression are associated with poor clinico-pathologic features and poor survival in patients with oesophageal adenocarcinoma.
Springer